Programme Thesis
The EIC Accelerator provides substantial non-dilutive grant and equity funding (up to €2.5M grant plus equity) to deep-tech and biotech startups with high-risk, high-impact innovations that can scale globally. It exists to bridge the funding gap for European and EU-incorporated ventures developing breakthrough technologies, particularly those with a strong scientific foundation and commercial potential.
Selection Criteria
Eligibility: SME registered in an EU Member State or Horizon Europe associated country (applicant must incorporate in EU before funding). Scoring rubric: (1) Excellence – breakthrough innovation, scientific/technological novelty, clear value proposition; (2) Impact – market potential, scalability, EU strategic autonomy, job creation; (3) Implementation – credible business plan, team capability, risk management. Reviewer priorities: deep tech readiness (TRL 5-8), clear path to market, strong IP strategy, team’s technical and entrepreneurial competence.
Past Winners / Cohort Profiles
Past winners include early-stage deep-tech startups in biotech, AI, and health (e.g., neurotech, drug discovery platforms, medical devices). Typical archetype: a spin-out from a European university or research institute with a patented technology, a multidisciplinary team (scientists + business co-founders), and a clear go-to-market plan. Named examples not found on the extracted page, but common profiles include companies like Neuroelectrics (neurostimulation) and Iktos (AI drug discovery).
Ideal Candidate Fingerprint
A deep-tech startup incorporated in the EU, with a patented or patent-pending breakthrough technology (TRL 5-7), a strong scientific co-founder with domain expertise, and a business co-founder with commercial experience. The venture should address a large market (e.g., healthcare, biotech) with clear EU strategic relevance and a scalable business model.
Recommended Framing
Eniola should position his CCT model and associated platforms (IMPRINT, TOPOLOGIX) as a breakthrough deep-tech venture for addiction treatment, with a provisional patent and strong endorsements from leading neuroscientists (Berridge, Gershman, Daw). Emphasize the validated computational framework (85.8% reduction in encoding probability) and the potential to spin out an EU-incorporated startup (e.g., in Austria via Graz) that addresses a global health crisis, aligning with EIC’s focus on biotech and societal impact.
Watch Out
Applicant is not yet EU-incorporated and is an independent researcher without a formal startup team or business co-founder. The EIC Accelerator requires an SME registered in an EU member state; Eniola would need to incorporate in Austria (or another EU country) before applying. Additionally, the programme typically funds later-stage deep tech (TRL 5-8), and Eniola’s technology is at an early stage (TRL 3-4). The lack of a business plan and pitch deck may be a competitive disadvantage.